163 related articles for article (PubMed ID: 22116550)
1. The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia.
de Bock CE; Ardjmand A; Molloy TJ; Bone SM; Johnstone D; Campbell DM; Shipman KL; Yeadon TM; Holst J; Spanevello MD; Nelmes G; Catchpoole DR; Lincz LF; Boyd AW; Burns GF; Thorne RF
Leukemia; 2012 May; 26(5):918-26. PubMed ID: 22116550
[TBL] [Abstract][Full Text] [Related]
2. Fat1 cadherin provides a novel minimal residual disease marker in acute lymphoblastic leukemia.
Ardjmand A; de Bock CE; Shahrokhi S; Lincz LF; Boyd AW; Burns GF; Thorne RF
Hematology; 2013 Nov; 18(6):315-22. PubMed ID: 23433465
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
[TBL] [Abstract][Full Text] [Related]
4. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
[TBL] [Abstract][Full Text] [Related]
5. Lymphoblastic lymphoma.
Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
[TBL] [Abstract][Full Text] [Related]
6. The BCL-2 protein in precursor B acute lymphoblastic leukemia in children.
Chaber R; Fiszer-Maliszewska L; Noworolska-Sauren D; Kwasnicka J; Wrobel G; Chybicka A
J Pediatr Hematol Oncol; 2013 Apr; 35(3):180-7. PubMed ID: 23511489
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
[TBL] [Abstract][Full Text] [Related]
8. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
9. Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy.
Tesfai Y; Ford J; Carter KW; Firth MJ; O'Leary RA; Gottardo NG; Cole C; Kees UR
Leuk Res; 2012 Mar; 36(3):299-306. PubMed ID: 21889797
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
12. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
13. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
[TBL] [Abstract][Full Text] [Related]
14. High nerve growth factor receptor (p75NTR) expression is a favourable prognostic factor in paediatric B cell precursor-acute lymphoblastic leukaemia.
Troeger A; Gudowius S; Escherich G; den Boer ML; Glouchkova L; Ackermann B; Meisel R; Laws HJ; Groeger M; Wessalowski R; Willers R; Harbott J; Pieters R; Goebel U; Janka-Schaub GE; Hanenberg H; Dilloo D
Br J Haematol; 2007 Nov; 139(3):450-7. PubMed ID: 17910636
[TBL] [Abstract][Full Text] [Related]
15. Differences in immunoglobulin heavy chain gene rearrangmeent patterns between bone marrow and blood samples in childhood precursor B-acute lymphoblastic leaukemia at diagnosis.
Beishuizen A; Verhoeven MA; Hählen K; van Wering ER; van Dongen JJ
Leukemia; 1993 Jun; 7(6):60-3. PubMed ID: 8315958
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
DiGiuseppe JA; Fuller SG; Borowitz MJ
Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
[TBL] [Abstract][Full Text] [Related]
17. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup.
Borssén M; Cullman I; Norén-Nyström U; Sundström C; Porwit A; Forestier E; Roos G
Exp Hematol; 2011 Dec; 39(12):1144-51. PubMed ID: 21914494
[TBL] [Abstract][Full Text] [Related]
18. E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia.
Corn PG; Smith BD; Ruckdeschel ES; Douglas D; Baylin SB; Herman JG
Clin Cancer Res; 2000 Nov; 6(11):4243-8. PubMed ID: 11106238
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of multidrug resistance gene (MDR1) at relapse in a child with acute lymphoblastic leukemia.
Kourti M; Vavatsi N; Gombakis N; Tzimagiorgis G; Sidi V; Koliouskas D; Athanassiadou F
Pediatr Hematol Oncol; 2006 Sep; 23(6):489-94. PubMed ID: 16849280
[TBL] [Abstract][Full Text] [Related]
20. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals.
Ommen HB; Nyvold CG; Braendstrup K; Andersen BL; Ommen IB; Hasle H; Hokland P; Ostergaard M
Br J Haematol; 2008 Jun; 141(6):782-91. PubMed ID: 18410450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
